Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA)

Journal of Applied Microbiology

Volumn 108, Issue 2, 2010, Pages 723-730

  Desbois, A P ^a   Lang, S ^b   Gemmell, C G ^c   Coote, P J ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Antibacterial; Chlorhexidine; Drug resistance; Ex vivo; Mupirocin; Synergy

Indexed keywords

DRUG THERAPY; PEPTIDES;

ANTIBACTERIALS; ANTIMICROBIAL PEPTIDE; CHLORHEXIDINE; DRUG-RESISTANCE; EX-VIVO; HUMAN SKIN; LYSOSTAPHIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MUPIROCIN; SYNERGY;

BACTERIA;

CHLORHEXIDINE GLUCONATE; GELLING AGENT; LYSOSTAPHIN; PROTEINASE; PSEUDOMONIC ACID; RANALEXIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIUM; BIOASSAY; DISINFECTION; ENZYME ACTIVITY; PEPTIDE; PH; REACTION KINETICS; SKIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL VIABILITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISINFECTION; DISK DIFFUSION; DRUG EFFICACY; DRUG POTENTIATION; EX VIVO STUDY; HUMAN; HUMAN TISSUE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PH; SURFACE PROPERTY;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 74049161613     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/j.1365-2672.2009.04472.x     Document Type: Article

References (32)

1. Borg, M.A., de Kraker, M., Scicluna, E., van de Sande-Bruinsma, N., Tiemersma, E., Monen, J. Grundmann, H. (2007) Prevalence of methicillin- resistant Staphylococcus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countries. J Antimicrob Chemother 60, 1310 1315.
2. Chiller, K., Selkin, B.A. Murakawa, G.J. (2001) Skin microflora and bacterial infections of the skin. J Invest Dermatol 6, 170 174.
3. Clark, D.P., Durell, S., Maloy, W.L. Zasloff, M. (1994) A novel antimicrobial peptide from bullfrog (Rana catesbeiana) skin, structurally related to the bacterial antibiotic, polymyxin. J Biol Chem 14, 10849 10855.
4. Coates, A., Hu, Y., Bax, R. Page, C. (2002) The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov 1, 895 910.
5. Cosgrove, S.E., Sakoulas, G., Perencevich, E.N., Schwaber, M.J., Karchmer, A.W. Carmeli, Y. (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36, 53 59. (Pubitemid 36099097)
6. Desbois, A.P., Mearns-Spragg, A. Smith, V.J. (2009) A fatty acid from the diatom Phaeodactylum tricornutum is antibacterial against diverse bacteria including multi-resistant Staphylococcus aureus (MRSA). Mar Biotechnol 11, 45 52.
7. European Antimicrobial Resistance Surveillance Survey (2008) EARSS Annual Report 2007. Bilthoven : EARSS.
8. Garvey, L.H., Krøigaard, M., Poulsen, L.K., Skov, P.S., Mosbech, H., Venemalm, L., Degerbeck, F. Husum, B. (2007) IgE-mediated allergy to chlorhexidine. J Allergy Clin Immunol 120, 409 415.
9. Gemmell, C.G., Edwards, D.I., Fraise, A.P., Gould, F.K., Ridgway, G.L. Warren, R.E. (2006) Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 57, 589 608.
10. Gould, I.M. (2006) Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents 28, 379 384.
11. Graham, S. Coote, P.J. (2007) Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. J Antimicrob Chemother 59, 759 762.
12. Grundmann, H., Aires-de-Sousa, M., Boyce, J. Tiemersma, E. (2006) Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368, 874 885.
13. Hancock, R.E.W. (1997) Peptide antibiotics. Lancet 349, 418 422.
14. Hancock, R.E.W. Lehrer, R. (1998) Cationic peptides: a new source of antibiotics. Trends Biotechnol 16, 82 88.
15. Holm, S. (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6, 65 70.
16. Klein, E., Smith, D.L. Laxminarayan, R. (2007) Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13, 1840 1846.
17. Klevens, R.M., Morrison, M.A., Nadle, J., Petit, S., Gershman, K., Ray, S., Harrison, L.H., Lynfield, R. et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298, 1763 1771.
18. Krautheim, A.B., Jermann, T.H.M. Bircher, A.J. (2004) Chlorhexidine anaphylaxis: case report and review of the literature. Contact Dermatitis 50, 113 116.
19. Lee, I.H., Cho, Y. Lehrer, R.I. (1997) Effects of pH and salinity on the antimicrobial properties of clavanins. Infect Immun 65, 2898 2903.
20. Maillard, J.Y., Messager, S. Veillon, R. (1998) Antimicrobial efficacy of biocides tested on skin using an ex-vivo test. J Hosp Infect 40, 313 323.
21. Marr, A.K., Gooderham, W.J. Hancock, R.E.W. (2006) Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 6, 468 472.
22. McDonnell, G. Russell, A.D. (1999) Antiseptics and disinfectants: activity, action and resistance. Clin Microbiol Rev 12, 147 179.
23. Messager, S., Goddard, P.A., Dettmar, P.W. Maillard, J.Y. (2001) Determination of the antibacterial efficacy of several antiseptics tested on skin by an 'ex-vivo' test. J Med Microbiol 50, 284 292.
24. Muñoz, P., Hortal, J., Giannella, M., Barrio, J.M., Rodríguez-Créixems, M., Pérez, M.J., Rincón, C. Bouza, E. (2008) Nasal carriage of S. aureus increases the risk of surgical site infection after major heart surgery. J Hosp Infect 68, 25 31.
25. van Rijen, M., Bonten, M., Wenzel, R. Kluytmans, J. (2008) Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 4. doi : (accessed 18 May 2009).
26. Schindler, C.A. Schuhardt, V.T. (1964) Lysostaphin: a new bacteriolytic agent for the Staphylococcus. Proc Natl Acad Sci U S A 51, 414 421.
27. Shi, J., Zhang, G., Wu, H., Ross, C., Blecha, F. Ganz, T. (1999) Porcine epithelial β-defensin 1 is expressed in the dorsal tongue at antimicrobial concentrations. Infect Immun 67, 3121 3127.
28. Simor, A.E., Stuart, T.L., Louie, L., Watt, C., Ofner-Agostini, M., Gravel, D., Mulvey, M., Loeb, M. et al. (2007) Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 51, 3880 3886. (Pubitemid 350057784)
29. Tai, C.C., Nirvani, A.A., Holmes, A. Hughes, S.P.F. (2004) Methicillin-resistant Staphylococcus aureus in orthopaedic surgery. Int Orthop 28, 32 35.
30. Upton, A., Lang, S. Heffernan, H. (2003) Mupirocin and Staphyloccus aureus: a paradigm of emerging antibiotic resistance. J Antimicrob Chemother 51, 613 617.
31. Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms. Nature 415, 389 395.
32. Zhao, X. Drlica, K. (2001) Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33 (Suppl 3 S147 S156.